Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655064 maintenance in lupus nephritis
NCT03385564Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 2 trial of BI 655064 in lupus nephritis (LN), sponsored by Boehringer Ingelheim. Started Jan 2018; status: completed.
02
Drugs
BI 655064
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03385564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385564.